Hormonal therapy for acne
| Autor: | Shari Clarke, Rosalyn George, Diane Thiboutot |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
medicine.medical_specialty
Population Physiology Dermatology Spironolactone Flutamide chemistry.chemical_compound Dehydroepiandrosterone sulfate Internal medicine Acne Vulgaris medicine Humans education Cyproterone Acetate Isotretinoin Acne Mineralocorticoid Receptor Antagonists education.field_of_study business.industry Cyproterone acetate Androgen Antagonists medicine.disease Endocrinology chemistry Hormonal therapy Surgery Female business medicine.drug Contraceptives Oral |
| Zdroj: | Seminars in cutaneous medicine and surgery. 27(3) |
| ISSN: | 1558-0768 |
| Popis: | Acne affects more than 40 million people, of which more than half are women older than 25 years of age. These women frequently fail traditional therapy and have high relapse rates even after isotretinoin. Recent advances in research have helped to delineate the important role hormones play in the pathogenesis of acne. Androgens such as dihydrotestosterone and testosterone, the adrenal precursor dehydroepiandrosterone sulfate, estrogens, growth hormone, and insulin-like growth factors may all contribute to the development of acne. Hormonal therapy remains an important part of the arsenal of acne treatments available to the clinician. Women dealing with acne, even those without increased serum androgens, may benefit from hormonal treatments. The mainstays of hormonal therapy include oral contraceptives and antiandrogens such as spironolactone, cyproterone acetate, or flutamide. In this article, we discuss the effects of hormones on the pathogenesis of acne, evaluation of women with suspected endocrine abnormalities, and the myriad of treatment options available. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|